Progress of exosomal PD-L1 in diagnosis and treatment of non-small cell lung cancer

doi:10.16352/j.issn.1001-6325.2023.09.1457

Abstract

Abstract: Exosomal PD-L1(exoPD-L1) is secreted by cancer cells in some patients with non-small cell lung cancer and this molecule participates in the development of tumors. As liquid biopsy detection, the detection of exosomal PD-L1 has a great deal of advantages, such as non-invasive and stable. Furthermore, exosomal PD-L1 has a bright prospect in early diagnosis in lung cancer, which also has close contact with TNM of non-small cell lung cancer. Exosomal PD-L1 is related to tumor tissue PD-L1 and can be used to select people who in deed suit immumunotherapy.Monitoring exosomal PD-L1 dynamically is meaningful for evaluating the effects of immunotherapy in patients with non-small cell lung cancer. Study has found that blocking the secretion of exosomal PD-L1 could assist immunotherapy. The application of exosomal PD-L1 is quite potential to the treatment of patients at advanced stage of non-small cell lung cancer.

Key words: non-small cell lung cancer, exosome, PD-L1, diagnosis, immunotherapy

CLC Number:

R734.2

YAN Chenhong, JIN Er. Progress of exosomal PD-L1 in diagnosis and treatment of non-small cell lung cancer[J]. Basic & Clinical Medicine, 2023, 43(9): 1457-1461.

References 28

[1]	Osmani L, Askin F, Gabrielson E, et al. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy[J]. Semin Cancer Biol, 2018, 52: 103-109.
[2]	Ma Y, Marinkova R, Nenkov M, et al. Tumor-intrinsic PD-L1 exerts an oncogenic function through the activation of the Wnt/β-catenin pathway in human non-small cell lung cancer[J]. Int J Mol Sci, 2022, 23:11031. doi: 10.3390/ijms231911031.
[3]	Zhang J, Zhu Y, Guan M, et al. Isolation of circulating exosomes and identification of exosomal PD-L1 for predicting immunotherapy response[J]. Nanoscale, 2022, 14:8995-9003.
[4]	Yoh KE, Lowe CJ, Mahajan S, et al. Enrichment of circulating tumor-derived extracellular vesicles from human plasma[J]. J Immunol Methods, 2021;490:1129363. doi:10.1016/j.jim.2020.112936.
[5]	杨旭东,于红亮,李静,等.巨噬细胞J774A.1外泌体促进结直肠癌细胞系MC38和CT26的增殖和迁移[J]. 基础医学与临床, 2021, 41:799-804.
[6]	彭晓潇,刘思思,宋丹妮,等.非小细胞肺癌血浆外泌体PD-L1检测的可行性研究[J]. 循证医学, 2019, 19:119-123.
[7]	Zhang W, Zhong W, Wang B, et al. ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression[J].Dev Cell, 2022, 57:329-343.
[8]	Ji C, Yang S, Feng M, et al. PD-L1-positive exosomes suppress antitumor immunity by inducing tumor-specific CD8+ T cell exhaustion during metastasis[J]. Cancer Sci, 2021,112: 3437-3454.
[9]	Kim DH, Kim H, Choi YJ, et al. Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer[J]. Exp Mol Med, 2019,51: 1-13.
[10]	Wu Y, Zeng X, Gan Q. A compact surface plasmon resonance biosensor for sensitive detection of exosomal proteins for cancer diagnosis[J].Methods Mol Biol, 2022, 2393:3-14.
[11]	Yang Y, Kannisto E, Yu G, et al. An immuno-biochip selectively captures tumor-derived exosomes and detects exosomal RNAs for cancer diagnosis[J]. ACS Appl Mater Interfaces, 2018, 10:43375-43386.
[12]	Sha L, Bo B, Yang F, et al. Programmable DNA-fueled electrochemical analysis of lung cancer exosomes[J]. Anal Chem, 2022, 94:8748-8755.
[13]	Li C, Li C, Zhi C, et al. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients[J]. J Transl Med, 2019, 17:355. doi: 10.1186/s12967-019-2101-2.
[14]	Zhang Z, Jin W, Xu K, et al. Blood exosome PD-L1 is associated with PD-L1 expression measured by immunohistochemistry, and lymph node metastasis in lung cancer[J], Tissue Cell, 2022, 79:101941. doi:10.1016/j.tice.2022.101941.
[15]	Shimada Y, Matsubayashi J, Kudo Y, et al. Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer[J]. Sci Rep, 2021, 11: 7830. doi:10.1038/s41598-021-87575-3.
[16]	Yu S, Shi M, Feng J. Expression of PD-L1 in plasma exosomes of NSCLC patients and its associations with PD-L1 expression of corresponding tumour tissues[J]. Ann Oncol, 2019, 30:v43. doi:10.1093/annonc/mdz239.
[17]	Wu F, Gu Y, Kang B, et al. PD-L1 detection on circulating tumor-derived extracellular vesicles (T-EVs) from patients with lung cancer[J]. Transl Lung Cancer Res, 2021, 10:2441-2451.
[18]	Yue C, Jiang Y, Li P, et al. Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy[J]. Oncoimmunology, 2018, 7:e1438111. doi:10.1080/2162402X.2018.1438111.
[19]	Wang Y, Niu X, Cheng Y, et al. Exosomal PD-L1 predicts response with immunotherapy in NSCLC patients[J].Clin Exp Immunol, 2022, 208:316-322.
[20]	Zhang C, Fan Y, Che X, et al. Anti-PD-1 therapy response predicted by the combination of exosomal PD-L1 and CD28[J].Front Oncol, 2020, 10:760. doi:10.3389/fonc.2020.00760.
[21]	De Miguel-Perez D, Russo A, Arrieta O, et al. Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer[J].J Exp Clin Cancer Res, 2022, 41:186. doi:10.1186/s13046-022-02379-1.
[22]	Del Re M, Marconcini R, Pasquini G, et al. PD-L1 mRNA expression in plasma-derived exosomes is associ-ated with response to anti-PD-1 antibodies in melanoma and NSCLC[J]. Br J Cancer, 2018, 118: 820-824.
[23]	Cordonnier M, Nardin C, Chanteloup G, et al. Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients[J]. J Extracell Vesicles, 2020, 9:1710899. doi:10.1080/20013078.2019.1710899.
[24]	Yang Q, Chen M, Gu J, et al. Novel biomarkers of bynamic blood PD-L1 expression for immune checkpoint inhibitors in advanced non-small-cell lung cancer patients[J]. Front Immunol, 2021, 12:665133.doi:10.3389/fimmu.2021.665133.
[25]	Hong W, Xue M, Jiang J, et al. Circular RNA circ-CPA4/let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC)[J]. J Exp Clin Cancer Res, 2020, 39:149. doi:10.1186/s13046-020-01648-1.
[26]	Lee CH, Bae JH, Choe EJ, et al. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1[J]. Theranostics, 2022, 12:1971-1987.
[27]	Yin Z, Yu M, Ma T, et al. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1[J]. J Immunother Cancer, 2021, 9:e001698. doi:10.1136/jitc-2020-001698.
[28]	Xie L, Li J, Wang G, et al. Phototheranostic metal-phenolic networks with antiexosomal PD-L1 enhanced ferroptosis for synergistic immunotherapy[J].J Am Chem Soc, 2022, 144:787-797.